Before she was 35, Suki Tipp and her family lived what she would describe as a busy, but relatively normal life. But then ...

Blueprint Medicines Corporation (Nasdaq: BPMC) today reported financial results, provided a business update for the first ...

A prostate cancer biomarker test that utilizes genes indicating high-grade prostate cancer appears highly accurate.

Among more than 1,300 patients diagnosed with HCC, the median survival reached 37 months for those with screening-detected ...

A new history of Indonesia’s fight for independence reveals the cruel means by which the Dutch tried to hold on to their ...

Harvard’s endowment is currently $50.7 billion. That means that the first year, the state would extract about $1.25 billion ...

Suki Tipp and her clinician, Dr. Pankit Vachhani, join Marc to share details on the burden of living with indolent systemic ...

Jill Zinsmeyer came to Austin for love, but Austin didn't love her. Living in Napa Valley, Calif., before the move, Zinsmeyer ...

Blueprint boosts Ayvakit peak sales estimate to $2B as key rare disease expansion accelerates Meanwhile, Blueprint these days ...

Health experts have warned against underestimating the risks of "indolent tumors" as China observes its 30th "National ...

Lori J. Wirth, MD, discusses the background and design of the phase 3 SELECT trial of lenvatinib vs placebo for the treatment ...

Earnings Per Share (EPS) Q1 2024: Reported at $1.45 basic and $1.40 diluted, outperforming the estimated EPS of -$1.66. AYVAKIT Net Product Revenues: Reached $92.5 million in Q1 2024, with full-year ...